N-[5-(3-methoxyphenyl)-2-oxo-5-phenyl-3,4-dihydro-1H-1,4-benzodiazepin-3-yl]piperidine-4-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[5-(3-methoxyphenyl)-2-oxo-5-phenyl-3,4-dihydro-1H-1,4-benzodiazepin-3-yl]piperidine-4-carboxamide
• 化学式: C₂₈H₃₀N₄O₃
• 分子量: 470.6
• InChiKey: DBFXTMPCCTUNNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  91.5
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Process for Preparing Benzodiazepines
  申请人：Dowdell Verity

  公开号：US20070293482A1

  公开（公告）日：2007-12-20

  A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R 1 represents C 1-6 alkyl, aryl or heteroaryl; each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano, —CO 2 R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″, wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; n is from 0 to 3; X represents —NH—, —N(C 1 -C 6 alkyl)-, —CO—, —CO—NR′—, —S(O)— or —S(O) 2 —, wherein R′ is hydrogen or a C 1 -C 6 alkyl group; and R 4 represents hydrogen; or —CO—R 4 ′ or —CO—NH—R 4 ′ , wherein R 4 ′ is a C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C 1 -C 6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a —(C 1 -C 4 alkyl)-X 1 —(C 1 -C 4 alkyl)-X 2 —(C 1 -C 4 alkyl) group, wherein X 1 represents —O—, —S— or —NR′—, wherein R′ represents H or a C 1 -C 4 alkyl group and X 2 represents —CO—, —SO— or —SO 2 —; or R 4 ′ represents -A 1 -Y-A 2 , wherein: A 1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; Y represents a direct bond or a C 1 -C 4 alkylene, —SO 2 —, —CO—, —O—, —S or —NR′—, wherein R′ is a C 1 -C 6 alkyl group; and A 2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; or R 4 is a group selected from aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— and -ZR 5 , wherein: Z represents —CO—, —S(O)— or —S(O) 2 ′; and R 5 represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-(C 1-6 alkyl)-O—, heteroaryl-(C 1-6 alkyl)-O—, carbocyclyl-(C 1-6 alkyl)-O—, heterocyclyl-(C 1-6 alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)- or heterocyclyl-(C 1-6 alkyl)-; or a pharmaceutically acceptable salt thereof; which process comprises: (a) subjecting a racemic benzodiazepine derivative of formula: (IIa): wherein R 1 , R 3 , R 4 , n and X are as defined above, and R 2 represents an amino protecting group, to crystallisation induced dynamic resolution to yield a benzodiazepine derivative of formula (II): wherein, R 1 , R 2 , R 3 , R 4 , n and X are as defined above; and (b) deprotecting the benzodiazepine derivative of formula (II) as defined above to yield a benzodiazepine derivative of formula (I) or a pharmaceutically acceptable form thereof as defined above.
• US8119630B2
  申请人：——

  公开号：US8119630B2

  公开（公告）日：2012-02-21